血清TGF-β1和IL-23在胃癌诊断中的临床应用价值

Clinical Significance of Serum TGF-β1 and IL-23 in The Diagnosis of Gastric Cancer

目的 研究慢性胃溃疡及胃癌患者血清中转化生长因子β1（TGF-β1）和白介素-23（IL-23）的表达情况,探讨TGF-β1和IL-23在胃癌防治的临床价值。方法 采用ELISA法检测胃癌组（83例）、胃溃疡组（184例）以及正常对照组（58例）血清TGF-β1和IL-23水平,并比较不同病理参数胃癌患者血清TGF-β1和IL-23水平的差异。结果 胃癌组血清TGF-β1水平为（15.96±3.92）ng/mL、IL-23为（645.25±234.18）ng/mL,均高于正常对照组〔（9.87±2.86）ng/mL、（372.75±89.27）ng/mL〕和胃溃疡组〔（10.10±3.58）ng/mL、（496.10±108.32）ng/mL〕,差异均有统计学意义（P〈0.05）;胃癌Ⅰ~Ⅱ期、Ⅲ期及Ⅳ期患者血清TGF-β1水平依次升高,各期间差异均有统计学意义（P〈0.05）。低分化胃癌血清TGF-β1水平高于高-中分化胃癌,有淋巴结转移者血清TGF-β1水平高于无淋巴结转移者,差异均有统计学意义（P〈0.05）;在不同肿瘤直径以及不同位置肿瘤患者血清TGF-β1水平差异无统计学意义（P〉0.05）。Ⅰ~Ⅱ期胃癌患者血清IL-23水平高于Ⅲ期及Ⅳ期,差异有统计学意义（P〈0.05）;不同分化程度、淋巴结转移与否、不同肿瘤直径以及不同位置肿瘤患者血清IL-23水平比较差异均无统计学意义（P〉0.05）。结论TGF-β1和IL-23在判定胃癌病理分期和恶性程度方面有重要的参考价值。

Objective To study the serum transforming growth factor β1 （TGF-β1） and interleukin -23 （IL-23） expression in the patients with chronic gastric ulcer or gastric cancer, and to investigate the clinical value of TGF-β1 and IL-23 on the prevention and treatment of gastric cancer. Methods The serum levels of TGF-[31 and IL-23 in cancer group （83 cases）, gastric ulcer group （184 cases）, and control group （58 cases） were detected by using ELISA assay method. The difference of serum TGF-β1 and IL-23 levels in patients with gastric cancer with different pathological parameters were compared. Results The serum levels of TGF-β1 （（15.96±3.92） ng/mL） and IL-23 （645.25±234.18） ng/mL in gastric cancer group were higher than those of the gastric ulcer group （10.10±3.58） ng/mL, （496A0±108.32） ng/mL） and normal control group （9.87±2.86） ng/mL, （372.75±89.27） ng/mL）, the difference were statistically significant （P〈0.05）. The levels of serum TGF-β1 in gastric cancer patients of stage Ⅰ,Ⅱ,Ⅲ and Ⅳ were successively increased, and the differences were statistically significant （P〈0.05）. The levels of serum TGF-β1 in poorly differentiated gastric cancer or with lymph node metastasis patients were higher than those in high-middle differentiation or without lymph node metastasis patients, the difference were statistically significant （P〈0.05）. There were no significant difference in the levels of serum TGF-β1 between different tumor diameter and different location （P〉0.05）. The level of serum IL-23 in patients with stage Ⅰ -Ⅱ was higher than that in stage Ⅲ and Ⅳ, the difference was statistically significant （P〈0.05）. Ther were no significant difference in serum IL-23 levels between the different degree of differentiation, lymph node metastasisor not, different tumor diameter and different location of the tumor （P〉0.05）. Conclusion TGF-β1 and IL-23 have important reference value in judging the stage and malignancy degree of gastric cancer.